Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Toxic Reactions: Overview

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early Total vs Conventional Feeding between 27-32 weeks' gestation: A Randomized Controlled Trial.

Neonatology·2026

Same author

Ram cannula vs nasal mask interface for providing CPAP in preterm neonates (< 34 weeks) with respiratory distress syndrome in a low- and middle-income country: an open-label, non-inferiority randomized controlled trial.

European journal of pediatrics·2026

Same author

Bioconjugates for breast cancer theranostics: improving target selectivity and treatment efficacy.

Expert opinion on drug delivery·2026

Same author

Prognosis of neonates receiving invasive mechanical ventilation in low-resource settings: a systematic review and prognostic meta-analysis.

European journal of pediatrics·2026

Same author

The Reemergence of Congenital Syphilis-Maternal and Fetal Risks and Consequences.

Journal of epidemiology and global health·2026

Same author

Evaluation of Efficacy of Bupivacaine vs Articaine for Postoperative Pain Management in Open Reduction of Fracture of Mandible- an <i>in vivo</i> study.

Journal of pharmacy & bioallied sciences·2026

Same journal

Incidence of Hepatitis C Virus and Other Bloodborne Virus Infections Among Nonurban Residents of Fairfield and New Haven Counties, Connecticut Who Inject Drugs.

Connecticut medicine·2021

Same journal

Remarks from the Annual Meeting.

Connecticut medicine·2018

Same journal

Address of the Outgoing President: Evolution.

Connecticut medicine·2018

Same journal

Address of the New President: One Society.

Connecticut medicine·2018

Same journal

Post Integration Trauma Syndrome (PITS).

Connecticut medicine·2018

Same journal

New Federal Drug Administration Fluoroquinolone Warning and a Practical Approach to Managing Patients.

Connecticut medicine·2018

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Mesalamine lung toxicity.

Neha Jain¹, Carol Petruff, Tapas Bandyopadhyay

¹N University of Connecticut Health Center, USA.

Connecticut Medicine

|June 1, 2010

Summary

This summary is machine-generated.

Lung toxicity from 5-aminosalicylate (5-ASA) agents like mesalamine is rare. This case highlights mesalamine-induced lung damage, presenting as shortness of breath and requiring prompt drug discontinuation for recovery.

Related Experiment Videos

Last Updated: Jun 12, 2026

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Area of Science:

Pulmonology
Gastroenterology
Pharmacology

Background:

Ulcerative colitis (UC) is often treated with 5-aminosalicylate (5-ASA) agents, primarily mesalamine.
Mesalamine is generally considered safe, with lung toxicity being an exceptionally rare adverse effect.

Observation:

A 48-year-old male UC patient developed progressive dyspnea while on oral mesalamine.
Chest imaging showed diffuse, patchy ground-glass opacities.
Pulmonary function tests revealed a restrictive defect and reduced diffusion capacity.

Findings:

The patient's respiratory symptoms and imaging findings resolved rapidly after discontinuing mesalamine.
This clinical course strongly suggests mesalamine-induced lung injury.

Implications:

Mesalamine-induced lung damage should be considered in patients with unexplained respiratory symptoms during 5-ASA therapy.
Early recognition and drug withdrawal are crucial for managing this rare but potentially serious adverse event.
This case underscores the importance of a comprehensive differential diagnosis in patients with UC and new-onset pulmonary complaints.